Serum soluble IL-6 receptor concentrations correlate with stages of multiple myeloma defined by serum β2-microglobulin and C-reactive protein

International Journal of Hematology

Volumn 66, Issue 3, 1997, Pages 367-371

  Kyriakou, D ^a   Papadaki, H ^a   Eliopoulos, A G ^a   Foudoulakis, A ^a   Alexandrakis, M ^a   Eliopoulos, G D ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Interleukin 6 (IL 6); Multiple myeloma; Soluble interleukin 6 receptor (sIL 6R)

Indexed keywords

BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; INTERLEUKIN 6 RECEPTOR;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; ENZYME ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; RECEPTOR BINDING; REFERENCE VALUE;

EID: 0031257715     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0925-5710(97)00055-8     Document Type: Article

References (14)

1. Yasukawa K, Saito T, Fukunaga T et al. Purification and characterization of soluble human IL-6 receptor expressed in CHO cell. J Biochem. 108:1990;673-676.
2. Honda M, Yamamoto S, Cheng M et al. Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J Immunol. 148:1992;2175-2180.
3. Gaillard JP, Bataille R, Brailly H et al. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol. 23:1993;820-824.
4. Ohtani K, Ninomiya H, Hasegawa Y et al. Clinical significance of elevated soluble interleukin-6 receptor levels in sera of patients with plasma cell dyscrasias. Br J Haematol. 91:1995;116-120.
5. Kyrtsonis M, Dedoussis G, Zervas C et al. Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma. Br J Haematol. 93:1966;420-422.
6. Bataille R, Jourdan M., Zhang X-G, Klein B Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest. 84:1989;2008-2011.
7. Papadaki H., Kyriakou D., Foudoulakis A., Markidou F., Alexandrakis M., Eliopoulos G.D. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of the activity of the disease. Acta Haematol. 97:1997;191-195.
8. 2-microglobulin produce a simple and powerful myeloma staging system. Blood. 80:1992;733-737.
9. Durie BGM, Salmon SE A clinical staging system for multiple myeloma. Cancer. 36:1975;842-854.
10. Zhang X-G, Klein B, Bataille R Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood. 74:1989;11-13.
11. Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell. 63:1990;1149-1157.
12. 3H-thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy. Br J Haematol. 58:1984;689-696.
13. Goto H, Shimazaki C, Tatsumi T et al. Mouse anti-human interleukin-6 receptor monoclonal antibody inhibits proliferation of fresh human myeloma cells in vitro. Jpn J Cancer Res. 85:1994;958-965.
14. Taga T, Hibi M, Hirata Y et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell. 58:1989;573-581.